# US 2026/0007741 A1 · Lipid nanoparticles for delivery of nucleic acids and vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0007741 A1
- Document ID: US20260007741A1
- Status: Published application
- Kind: A1
- Application number: 19/243,498
- Filed: 2025-06-19
- Published: 2026-01-08
- Earliest claimed: 2024-06-21
- Assignees: Akagera Medicines, Inc.
- Applicants: Akagera Medicines, Inc.
- Inventors: Daryl C. Drummond; Ross Fulton; Mark E. Hayes; Dmitri Kirpotin; Alexander Koshkaryev
- Web page: https://patentgrep.com/patent/US20260007741A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 9/5146: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/12: Viral antigens
- A61K 48/0041: {the non-active part being polymeric}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 2039/5154: {Antigen presenting cells [APCs], e.g. dendritic cells or macrophages}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C12N 2710/16734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2730/10134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18534: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aspects of the present disclosure provides for improved vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage.

## Claims

### Claim 1

A lipid nanoparticle (LNP) composition comprising a TLR-activating nucleic acid.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid is a RNA oligonucleotide or a DNA oligonucleotide.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid is a TLR9-activating DNA oligonucleotide and one or the nucleic acid is a TLR7/8-activating RNA oligonucleotide.

### Claim 4 (depends on 1)

The composition of claim 1, further comprising a TLR4 agonist.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the TLR4 agonist is selected from the group consisting of Monophosphoryl Lipid A (MPL), Monophosphoryl Lipid A-504, Monophosphoryl 3-Deacyl Lipid A, and Monophosphoryl Hexa-acyl Lipid A, and 3-Deacyl.

### Claim 6 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid is a TLR9-activating oligonucleotide, optionally CPG1018.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid comprises a TLR7 and/or TLR-8 activating RNA oligonucleotide.

### Claim 8 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid comprises both a TLR-activating DNA oligonucleotide and a TLR-activating RNA oligonucleotide.

### Claim 9 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid is a DNA comprising a CpG site.

### Claim 10 (depends on 9)

The composition of claim 9, wherein the TLR-activating nucleic acid activates human TLR9.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the CpG is selected from the group consisting of: CpG-ODN 1018 (SEQ ID NO. 2), CpG-ODN 2006 (SEQ ID NO. 3; also known as ODN 7909 or PF3512676), CpG-ODN 2216 (SEQ ID NO. 6), CpG-ODN 2336 (SEQ ID NO. 7) and CpG-ODN 2395 (SEQ ID NO. 8)

### Claim 12 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid comprises a TLR7 and/or TLR-8 activating nucleic acid selected from the group consisting of: R-0006 (SEQ ID NO. 25), R-1075 (SEQ ID NO. 11), 9.2dr (SEQ ID NO. 212), 9.3as (SEQ ID NO. 113), 9.2s (SEQ ID NO. 114) and HIV sequence 1 (SEQ ID NO. 116).

### Claim 13 (depends on 1)

The composition of claim 1, wherein the TLR-activating nucleic acid activates RIG-I.

### Claim 14 (depends on 13)

The composition of claim 13, wherein the TLR-activating nucleic acid is selected from the group consisting of: 3P-GFP2 (SEQ ID NO. 127) annealed with either SEQ ID NO. 128 or SEQ ID NO. 129, 3P-A24 (SEQ ID NO. 130) annealed with either SEQ ID NO. 133 or SEQ ID NO. 134, 3P-G24 (SEQ ID NO. 130) annealed with either SEQ ID NO. 140 or SEQ ID NO. 141, 3P-C24 (SEQ ID NO. 130) annealed with either SEQ ID NO. 147 or SEQ ID NO. 148 and 3P-U24 (SEQ ID NO. 151) annealed with either SEQ ID NO. 154 or SEQ ID NO. 155.

### Claim 15

A lipid nanoparticle (LNP) composition consisting of:
a. a nucleic acid antigen recognized by a germline-encoded pattern recognition receptor (PRR);
b. an ionizable cationic lipid comprising an ionizable cationic lipid at a N/P ratio of 4 to 6 relative to the mRNA, the ionizable cationic lipid present in the LNP composition in a total amount of 46-54 mol % of a total lipid content of the LNP composition;
c. one or more phospholipids selected from the group consisting of distearoylphosphatidylcholine (DSPC), hydrogenated soy phosphatidylcholine (HSPC), and dipalmitoylphosphatidylcholine (DPPC), in a total amount of 10-18 mol % of the total lipid content of the LNP composition;
d. one or more anionic phospholipids selected from the group consisting of dipalmitoylphosphatidyl-L-serine (DPPS), or distearoylphosphatidyl-L-serine (DSPS), distearoylphosphatidylglycerol (DSPG), and dipalmitoyphosphatidylglycerol (DPPG) in a total amount of 2-8 mol % of the total lipid content of the LNP composition;
e. PEG(2000)-dimyristoylglycerol (PEG-DMG) in a total amount of 1-3.5 mol % of the total lipid content of the LNP composition; and
f. cholesterol.

### Claim 16 (depends on 15)

The composition of claim 15, wherein the PRR recognizes a conserved microbial pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs).

### Claim 17 (depends on 16)

The composition of claim 16, wherein:
the nucleic acid antigen is a CpG oligodeoxynucleotide recognized by TLR9; or
the nucleic acid antigen is a ssRNA oligonucleotide recognized by TLR7 or TLR8; or
the nucleic acid antigen is a ssRNA oligonucleotide recognized by TLR7 and TLR8; or
the nucleic acid antigen is a RIG-I that recognizes uncapped 5′ triphosphate RNA (aka pppRNA, 3pRNA); or
the nucleic acid antigen is a 5′ppp ssRNA with polyuridine with interspersed guanosines (poly-U/UG), polyuridine with interspersed cytidines (poly-U/UC), or polyadenosine interspersed with guanosines (poly-A/AG) or with RNA regions enriched with polyuridine and interspersed guanosines (poly-U/UG), polyuridine with interspersed cytidines (poly-U/UC), polyadenosine interspersed with guanosines (poly-A/AG); or
the nucleic acid antigen encodes melanoma differentiation-associated protein 5 (MDA5); or
the nucleic acid antigen is selected from the group consisting of NOD2, LGP2, DDX1-DDX21-DHX36, DDX60, DHX9, DHX36, DDX41, AIM2, IF16, ZBP1, LRRFIP1, and STING; or
the nucleic acid antigen is a CpG oligodeoxynucleotide (ODN) 1018 (SEQ ID NO: 2); or
the nucleic acid antigen is a CpG-ODN 2006 (SEQ ID NO: 3); or
the nucleic acid antigen is TLR7/8 ssRNA oligonucleotide 5′-UUGUUGUUGUUGUUGUUGUU-3′ (SEQ ID NO: 25); or
the nucleic acid antigen is mRNA encoding for SARS-CoV-2 Spike protein (SEQ ID NO: 1); or
the nucleic acid antigen is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3; or
the nucleic acid antigen is a TLR-9 CpG-ODN adjuvant; or
the nucleic acid antigen is selected from the group consisting of SEQ ID NO:11-SEQ ID NO:117 (Table 55).

### Claim 18 (depends on 2)

The composition of claim 2, wherein the nucleic acid is selected from the group consisting of SEQ ID NO:118-SEQ ID NO:126 (Table 56) or SEQ ID NO:127-167 (Table 60).

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the lipid nanoparticle composition of claim 1.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the composition is a vaccine.
